ClinicalTrials.gg
CompletedNCT01241539Updated Apr 7, 2014Results posted

Pharmacokinetics of Dabigatran Etexilate (Pradaxa®) During Haemodialysis

A Phase 1 interventional study of Dabigatran etexilate and Dabigatran etexilate in Cardiovascular Diseases and Kidney Failure, Chronic, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 21 Years to 60 Years. Per ClinicalTrials.gov, last updated 2014-04-07.

Sponsored by Boehringer Ingelheim · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
7
Allocation
Non-randomized
Ages
21 Years to 60 Years
Sex
All
01

Study summary

The current study will allow the assessment of pharmacokinetics, pharmacodynamics, elimination rate and clearance of dabigatran etexilate during and following haemodialysis in ESRD patients.

02

Conditions studied

  • Cardiovascular Diseases
  • Kidney Failure, Chronic
03

In context

Cardiovascular Diseases

5,370 studies on the registry are indexed under Cardiovascular Diseases; 938 are open to participants now.

This study's enrollment of 7 is below the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • End stage renally disease (ESRD), undergoing haemodialysis
  • ESRD patients in relatively good health
  • Age 21 - 60 years inclusive
  • Signed and dated written prior to admission to the study

Exclusion criteria

Exclusion criteria:

  • laboratory or physical examination abnormalities (except for renal function tests or deviation of clinical laboratory values) that are related to renal impairment
  • Moderate and severe concurrent liver function impairment
  • Surgery of gastrointestinal tract (except appendectomy or herniotomy) or evidence of significant gastrointestinal motility problems
  • Recent or contemplated diagnostic or therapeutic procedures with potential for uncontrollable bleeding
  • Intake of medication, which influences the blood clotting
  • Subjects not able to understand and comply with protocol requirements, instructions and protocol-stated restrictions
  • For women with : no reliable
  • Participation in another trial with an drug (\<2 months prior to administration or during trial)
  • Scheduled to receive a donor kidney transplant during the course of the study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Dabigatran etexilate 110 mg

    Capsule, oral

    Drug: Dabigatran etexilate

  • Experimental
    Dabigatran etexilate 75 mg

    Capsule, oral

    Drug: Dabigatran etexilate

  • Experimental
    Dabigatran etexilate 150 mg

    Capsule, oral

    Drug: Dabigatran etexilate

Interventions

06

What researchers measure

Primary outcomes

  1. Dialysis Clearance of Dabigatran

    Dialysis clearance of dabigatran from blood (CLD,b) and dialysis clearance of dabigatran from plasma (CLD) were calculated and indicate how quickly dabigatran is cleared out from blood or plasma.

    Time frame: 4 hours

  2. Extent Cleared From Circulation (Plasma) During 1 Complete Cycle of Dialysis

    Extent of dabigatran that is removed from blood during one complete 4-hour cycle of dialysis was computed by the difference of plasma concentration at the start and at the end of dialysis relative to the start concentration and is therefore measured as a percentage.

    Time frame: 4 hours

  3. Plasma Concentration Extraction Ratio

    Plasma concentration extraction ratio was measured directly at the dialysis machine and computed as the difference of the predialysis plasma concentration and the postdialysis plasma concentration relative to the predialysis concentration on the percentage scale (minimum: 0 percent of extraction (worst), maximum: 100 percent of extraction).

    Time frame: 4 hours

Secondary outcomes

  1. Area Under the Curve Exposure to Dabigatran During the First 8 Hours Post Dose (AUC0-8h)

    Area under the concentration-time curve of total and free dabigatran in plasma over the time interval from 0 to 8 hours after the second and third administration of dabigatran.

    Time frame: Days 2 and 3

  2. Maximum Plasma Concentrations of Dabigatran (Cmax)

    Maximum measured concentration of total and free dabigatran in plasma after the second and third administration of dabigatran.

    Time frame: Days 2 and 3

  3. Time to Maximum Plasma Concentration (Tmax)

    Time to maximum plasma concentration of total and free dabigatran in plasma after the third administration of dabigatran.

    Time frame: Day 3

  4. Coagulation Parameters

    Assessment of blood coagulation parameters 'activated partial thromboplastin time' (aPTT) and 'factor IIa inhibition' (anti-FIIa) measured with the diluted thrombin time assay. Time to the formation of a fibrin clot (coagulation) is measured in seconds.

    Time frame: Day 3

  5. Safety and Tolerability

    Tolerability refers to the number of non-tolerable patients as assessed through the subjective examination of adverse events (AE). Safety refers to the number of patients with treatment emergent AEs. These numbers are presented on the overall Dabigatran treatment.

    Time frame: 2 periods of 5 days each

  6. Additional Safety Parameters

    By study design abnormalities could be due to dialysis or Dabigatran.

    Time frame: 2 periods of 5 days each

07

Results

Posted Jul 27, 2012

Participant flow

Period 1
Participant flow — Period 1
MilestoneDabigatran
Started7
Completed7
Not completed0
Period 2
Participant flow — Period 2
MilestoneDabigatran
Started7
Completed7
Not completed0

Outcome measures

PrimaryDialysis Clearance of Dabigatran

Dialysis clearance of dabigatran from blood (CLD,b) and dialysis clearance of dabigatran from plasma (CLD) were calculated and indicate how quickly dabigatran is cleared out from blood or plasma.

Time frame:
4 hours
Reported as:
Geometric mean · mL/min
Dialysis Clearance of Dabigatran
mL/minDabigatran P1Dabigatran P2
Total dabigatran clearance (CLD,b) from blood161 ± 5.01241 ± 3.08
Total dabigatran clearance (CLD) from plasma120 ± 5.09183 ± 4.30
Free dabigatran clearance (CLD,b) from blood167 ± 4.60251 ± 2.17
Free dabigatran clearance (CLD) from plasma124 ± 4.48190 ± 3.68
PrimaryExtent Cleared From Circulation (Plasma) During 1 Complete Cycle of Dialysis

Extent of dabigatran that is removed from blood during one complete 4-hour cycle of dialysis was computed by the difference of plasma concentration at the start and at the end of dialysis relative to the start concentration and is therefore measured as a percentage.

Time frame:
4 hours
Reported as:
Geometric mean · Percentage
Extent Cleared From Circulation (Plasma) During 1 Complete Cycle of Dialysis
PercentageDabigatran P1Dabigatran P2
Total Dabigatran48.8 ± 10.959.3 ± 6.69
Free Dabigatran49.7 ± 9.1059.3 ± 6.13
PrimaryPlasma Concentration Extraction Ratio

Plasma concentration extraction ratio was measured directly at the dialysis machine and computed as the difference of the predialysis plasma concentration and the postdialysis plasma concentration relative to the predialysis concentration on the percentage scale (minimum: 0 percent of extraction (worst), maximum: 100 percent of extraction).

Time frame:
4 hours
Reported as:
Geometric mean · Percentage
Plasma Concentration Extraction Ratio
PercentageDabigatran P1Dabigatran P2
Total Dabigatran79.9 ± 9.0161.4 ± 9.54
Free Dabigatran82.6 ± 8.2163.7 ± 8.60
SecondaryArea Under the Curve Exposure to Dabigatran During the First 8 Hours Post Dose (AUC0-8h)

Area under the concentration-time curve of total and free dabigatran in plasma over the time interval from 0 to 8 hours after the second and third administration of dabigatran.

Time frame:
Days 2 and 3
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve Exposure to Dabigatran During the First 8 Hours Post Dose (AUC0-8h)
ng*hr/mLDabigatran P1Dabigatran P2
Total Dabigatran on Day 21230 ± 57.11140 ± 39.4
Total Dabigatran on Day 31280 ± 54.41180 ± 50.2
Free Dabigatran on Day 2907 ± 51.6802 ± 44.1
Free Dabigatran on Day 3839 ± 41.3752 ± 58.0
SecondaryMaximum Plasma Concentrations of Dabigatran (Cmax)

Maximum measured concentration of total and free dabigatran in plasma after the second and third administration of dabigatran.

Time frame:
Days 2 and 3
Reported as:
Geometric mean · ng/mL
Maximum Plasma Concentrations of Dabigatran (Cmax)
ng/mLDabigatran P1Dabigatran P2
Total Dabigatran on Day 2194 ± 53.1171 ± 36.2
Total Dabigatran on Day 3176 ± 54.1159 ± 50.2
Free Dabigatran on Day 2150 ± 47.3126 ± 38.1
Free Dabigatran on Day 3119 ± 43.7105 ± 57.3
SecondaryTime to Maximum Plasma Concentration (Tmax)

Time to maximum plasma concentration of total and free dabigatran in plasma after the third administration of dabigatran.

Time frame:
Day 3
Reported as:
Geometric mean · h
Time to Maximum Plasma Concentration (Tmax)
hDabigatran P1Dabigatran P2
Total Dabigatran1.49 ± 38.42.13 ± 74.1
Free Dabigatran1.35 ± 38.41.83 ± 27.3
SecondaryCoagulation Parameters

Assessment of blood coagulation parameters 'activated partial thromboplastin time' (aPTT) and 'factor IIa inhibition' (anti-FIIa) measured with the diluted thrombin time assay. Time to the formation of a fibrin clot (coagulation) is measured in seconds.

Time frame:
Day 3
Reported as:
Mean · sec
Coagulation Parameters
secDabigatran P1Dabigatran P2
Activated partial thromboplastin time (aPTT)46.91 ± 12.2244.26 ± 10.98
Factor IIa inhibition (anti-FIIa)43.27 ± 7.9943.09 ± 5.38
SecondarySafety and Tolerability

Tolerability refers to the number of non-tolerable patients as assessed through the subjective examination of adverse events (AE). Safety refers to the number of patients with treatment emergent AEs. These numbers are presented on the overall Dabigatran treatment.

Time frame:
2 periods of 5 days each
Reported as:
Number · Participants
Safety and Tolerability
ParticipantsDabigatran
Treatment emergent adverse events2
Assessment of tolerability by the investigator0
SecondaryAdditional Safety Parameters

By study design abnormalities could be due to dialysis or Dabigatran.

Time frame:
2 periods of 5 days each
Reported as:
Number · Participants
Additional Safety Parameters
ParticipantsDabigatran
Electrocardiogram (ECG) abnormalities0
Vital sign abnormalities0
Physical finding abnormalities0
Laboratory abnormalities: Haematology0
Laboratory abnormalities: Clinical chemistry0

Adverse events

Collected over 2 periods of 5 days each. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dabigatran—0/7 (0%)2/7 (28.6%)
Most frequent other events
Most frequent other events
EventDabigatran
HeadacheNervous system disorders1/7
EpistaxisRespiratory, thoracic and mediastinal disorders1/7

Baseline characteristics

Treated set (TS) included all 7 subjects who were dispensed trial medication and were documented to have taken at least 1 dose of investigational treatment.

Age, Continuous
Age, Continuous(Years)Dabigatran
Mean38.3 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)Dabigatran
Female0
Male7
08

Study locations

1 site
  • 1160.121.1 Boehringer Ingelheim Investigational Site
    Berlin, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010 and a primary completion of May 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2012, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2010
First posted
Nov 16, 2010
Start
Nov 2010
Primary completionActual
May 2011
Results first posted
Jul 27, 2012
Last update
Apr 7, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01241539
Responsible party
Sponsor
First posted
Nov 16, 2010
Start date
Nov 2010
Primary completion
May 2011
Results posted
Jul 27, 2012
Last update
Apr 7, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dabigatran

Start the discussion